{
  "ptid_time": "131_S_1389_2007-10-25",
  "img_path": "/data/qiuhui/data/adni/images/131_S_1389/2007-10-25/t1.nii.gz",
  "img_finding": "Image findings: ventricular volume measures 62,366 mm³, 61.9% above the reference mean. With a Z-score of 1.48 (93.1th percentile), this represents mild enlargement; hippocampal volume measures 5,836 mm³, 22.8% below the reference mean. With a Z-score of -2.22 (1.3th percentile), this represents significant atrophy; whole brain volume measures 944,369 mm³, 12.5% below the reference mean. With a Z-score of -1.62 (5.2th percentile), this represents moderate atrophy; entorhinal cortex volume measures 2,042 mm³, 50.2% below the reference mean. With a Z-score of -3.40 (0.0th percentile), this represents profound atrophy; fusiform gyrus volume measures 13,587 mm³, 27.9% below the reference mean. With a Z-score of -2.37 (0.9th percentile), this represents significant atrophy; middle temporal gyrus volume measures 11,430 mm³, 46.4% below the reference mean. With a Z-score of -4.17 (0.0th percentile), this represents profound atrophy. ",
  "text_data": "Age is 76.6 years. Gender is Male. Education: 18 years. MMSE: 28.0. APOEε4 alleles: 1.0. ",
  "true_diagnosis": "Diagnosis: MCI.",
  "gpt_diagnosis": "**Reasoning:** The imaging data shows significant atrophy in key Alzheimer's-related regions (hippocampus, entorhinal cortex, fusiform gyrus, middle temporal gyrus), with Z-scores well below the mean, suggesting neurodegeneration. However, the MMSE score of 28 is within the normal range (≥26), indicating preserved cognitive function despite structural changes.  \n\n**Diagnosis:** **Mild Cognitive Impairment (MCI)** (structural changes precede clinical symptoms, but no functional impairment yet).  \n\n**Confidence:** **Medium** (high confidence in neurodegeneration, but MCI diagnosis is tentative due to the normal MMSE; clinical correlation with episodic memory tests would strengthen the assessment).  \n\n*Note: APOE4 carrier status increases Alzheimer's risk, but alone is not diagnostic. Follow-up cognitive testing (e.g., MoCA, neuropsychological battery) and longitudinal monitoring are recommended.*",
  "timestamp": "2025-07-26T15:13:24.303997"
}